scholarly journals CYTOMORPHOLOGICAL DETECTION OF MALIGNANT EFFUSIONS IN NON-HODGKIN LYMPHOMA: AN INSTITUTIONAL EXPERIENCE IN A DEVELOPING COUNTRY

2019 ◽  
pp. 148-150
Author(s):  
BHAVNA NAYAL ◽  
GEETHA V
Keyword(s):  
Hodgkin Lymphoma ◽  
Systemic Disease ◽  
Tertiary Care ◽  
The Body ◽  
Lymphoid Cells ◽  
Low Grade ◽  
Detection Rates ◽  
Tissue Biopsy ◽  
Non Hodgkin Lymphoma ◽  
Lymphoid Cell Population

Objective: Lymphomatous effusions of the body cavity may be the presenting feature or develop later as a complication of systemic disease. The detection rate of lymphoma in cytologic specimen is low, especially in the absence of clinical details and ancillary studies. The present study was carried out to identify light microscopic features that are useful in identifying lymphomas on effusion cytology. Methods: A 5-year retrospective study of all patients with fluid cytology or tissue biopsy reported as suspicious or positive for non-Hodgkin lymphoma (NHL) in a tertiary care was done. The cytology, histopathology, and immunohistochemistry slides were reviewed. Results: A total of 27 cases were included in the study. Correlation with the histopathological sections of all the positive cases revealed that the cytomorphology of the abnormal lymphoid cells was monomorphous and similar to those seen in the tissue biopsy. Mercury drop karyorrhexis when present was characteristic of lymphomatous effusions. The detection rates of large cell lymphomas are higher than low-grade counterparts. Non-lymphomatous effusions showed heterogeneous lymphoid cell population and lacked karyorrhexis. Conclusion: Lymphomas can give rise to effusions. In the absence of resources in developing countries, it is important to distinguish lymphomatous effusion from a reactive process based on morphology. Monomorphous population of the lymphoid cells and presence of mercury drop karyorrhexis are useful morphological clues in identifying a lymphomatous effusion. Further, tuberculosis is a common non-neoplastic process that can be mistaken for a low-grade NHL.

scholarly journals Follicular Lymphoma: A Clinicopathological Analysis from a Tertiary care Institute in Southern India

2016 ◽  
Vol 8 ◽  
pp. 2016060 ◽  
Author(s):  
Mary Theresa Sylvia ◽  
Biswajit Dey ◽  
Debdatta Basu ◽  
Sajini Elizabeth Jacob ◽  
Rakhee Kar ◽  
...  
Keyword(s):  
Follicular Lymphoma ◽  
Hodgkin Lymphoma ◽  
Bone Marrow Involvement ◽  
Tertiary Care ◽  
Proliferation Index ◽  
Clinicopathological Parameters ◽  
Low Grade ◽  
Female Ratio ◽  
Non Hodgkin Lymphoma ◽  
Granulomatous Response

IntroductionFollicular lymphoma (FL) is an indolent chronic lymphoproliferative disorder of B-cells with variable clinical behaviour. It is the second most common subtype of Non-Hodgkin lymphoma in western countries but reported to have a lower incidence in Asia.Materials and methodsCases of FL diagnosed in the Department of Pathology of our Institute from January 2009 to June 2015 were included in the study. The clinicopathological parameters including staging, histological details and immunohistochemical markers CD20, CD10, Bcl2 and Ki67 were recorded in all the cases.ResultsOf the 497 cases of Non-Hodgkin Lymphoma reported during the study period, 36 (7.2%) cases were follicular lymphoma. The mean age was 50 years with male to female ratio of 3.2:1. Grade 1/ 2 was seen in 70% cases. 22 % cases had low grade with high proliferation index (Ki67 > 40%). Granulomatous response was seen in two cases. Diffuse large cell lymphoma component was present in four cases. Bone marrow involvement and peripheral blood spill was seen in 12 (37.5%) and six cases (18.8%) respectively. 72% cases were in stage 3 or 4.ConclusionIncidence of FL was lower in our study than other Indian studies. FL presented in the elderly, with male predominance and disseminated stage. Features of low grade with high proliferation index, granulomatous response, leukemic involvement and transformation to high grade lymphoma are highlighted in the study.

Vaccine strategies in the treatment of low-grade non-Hodgkin lymphoma

2008 ◽  
Vol 109 (3-5) ◽  
pp. 230-232 ◽  
Author(s):  
Anna Koumarianou ◽  
Pantelis Kountourakis ◽  
Theophanis Economopoulos
Keyword(s):  
Hodgkin Lymphoma ◽  
Low Grade ◽  
Non Hodgkin Lymphoma

Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events

Blood ◽  
2010 ◽  
Vol 115 (26) ◽  
pp. 5322-5328 ◽  
Author(s):  
Vanesa Caruso ◽  
Augusto Di Castelnuovo ◽  
Susana Meschengieser ◽  
Maria A. Lazzari ◽  
Giovanni de Gaetano ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Meta Analysis ◽  
Hematologic Malignancies ◽  
Incidence Rates ◽  
Clinical Implications ◽  
Low Grade ◽  
Thrombotic Risk ◽  
Non Hodgkin Lymphoma ◽  
Thrombotic Complications ◽  
Exact Maximum Likelihood

AbstractThrombotic complications in hematologic malignancies have important clinical implications. In this meta-analysis we sought to obtain accurate estimates of the thrombotic risk in lymphoma patients. Articles were searched in electronic databases and references. Eighteen articles were identified (29 cohorts, 18 018 patients and 1149 events). Pooled incidence rates (IRs) were calculated by the use of a method based on the exact maximum likelihood binomial distribution. The global IR of thrombosis was 6.4% (95% confidence interval [CI] 6.0%-6.8%). The global IRs of venous or arterial events were 5.3% (95% CI, 5.0%-5.7%) and 1.1% (95% CI, 0.9%-1.2%), respectively. The IR of thrombosis observed in subjects with non-Hodgkin lymphoma (NHL) was 6.5% (95% CI, 6.1%-6.9%), significantly greater than that observed for patients with Hodgkin lymphoma (4.7%; 95% CI, 3.9%-5.6%). Within NHL, patients with high-grade disease had a greater risk of events (IR 8.3%; 95% CI, 7.0%-9.9%) than low-grade disease (IR 6.3%; 95% CI, 4.5%-8.9%). This meta-analysis shows that the IR of thrombosis in lymphoma patients is quite high, especially in those with NHL at an advanced stage of the disease. These results may help better defining lymphoma populations at high thrombotic risk, to whom prophylactic approaches could be preferentially applied.

ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 13-14 ◽  
Author(s):  
Tae Min Kim ◽  
Nehal Lakhani ◽  
Justin Gainor ◽  
Manali Kamdar ◽  
Philip Fanning ◽  
...  
Keyword(s):  
Immune Response ◽  
Hodgkin Lymphoma ◽  
Research Funding ◽  
Tolerability Profile ◽  
Low Grade ◽  
Publicly Traded ◽  
Private Company ◽  
Non Hodgkin Lymphoma ◽  
Time Of Presentation

Background: CD47 is a myeloid checkpoint upregulated by tumor cells to evade the host's immune response. The high affinity CD47 blocker fusion protein, ALX148, is linked to an inactive immunoglobulin Fc region to minimize toxicity. ALX148 is half the size of an antibody, has been well tolerated, and enhances the innate and adaptive immune response against cancer in combination with anticancer therapeutics across solid and hematologic tumors (ASCO 2020 #3056, EHA 2020 #EP1247). Characterization of ALX148's tolerability profile and antitumor activity in combination with rituximab are reported in patients (pts) with non-Hodgkin Lymphoma (NHL). Methods: Patients with relapsed or refractory CD20-positive B-cell NHL for which no curative therapy was available received ALX148 (10 mg/kg QW or 15 mg/kg QW) in combination with rituximab (375 mg/m2 weekly for 4 doses followed by once monthly for 8 doses). The primary endpoint for the safety population was dose limiting toxicity (DLT). Tumor response, pharmacokinetic (PK), and pharmacodynamic (PD) markers were assessed in all pts. Data are reported as of 30Jun2020 in these fully enrolled cohorts with final data to be updated at the time of presentation. Results: A total of 33 patients with NHL were administered ALX148 in combination with rituximab. Twenty-two pts with median age of 66 years (range 32-80) were administered ALX148, 10 mg/kg QW (ALX10), in combination with rituximab [DLBCL, n=11; mantle cell lymphoma (MCL), n=4; follicular lymphoma (FL), n=5; and marginal zone lymphoma (MZL), n=2]. Eleven pts with median age of 64 years (range 53-78) were administered ALX148, 15 mg/kg QW (ALX15), in combination with rituximab (DLBCL, n=6; MCL, n=1; FL, n=3; and MZL, n=1). There have been no DLTs reported in the fully enrolled safety cohorts, and the MTD of ALX148 in combination with rituximab has not been reached. The maximum ALX148 administered dose is 15 mg/kg QW. Twenty-eight pts experienced any AE, while 16 pts reported mostly low grade treatment-related adverse events (TRAE). The most common TRAEs were rash (21%, n=7), fatigue (9%, n=3), anemia, nausea, neutropenia, and pruritus (6%, n=2 each). With a median follow up of 14 months, objective responses were observed across all histologies in response-evaluable ALX10 pts: 40.9% ORR (4CR,5PR, 6SD, n=22 total) and with a median follow up of 9 months in ALX15 pts: 63.6% ORR (3CR, 4PR, 1SD, n=11 total). Preliminary results indicate favorable ALX148 PK and near complete CD47 receptor occupancy across the dosing interval. Final results will be updated at time of presentation. Conclusions: ALX148 demonstrates excellent tolerability with durable responses in combination with rituximab in patients with relapsed/refractory NHL. The MTD of ALX148 in combination with rituximab was not reached. Encouraging preliminary activity and favorable PK/PD characteristics in combination with rituximab were observed at all dose levels with greater objective response rates reported at the MAD of 15 mg/kg QW. Disclosures Kim: Boryung: Consultancy; Voronoi: Consultancy; F. Hoffmann-La Roche Ltd/Genentech, Inc.: Consultancy; Sanofi: Consultancy; Novartis: Consultancy; Takeda: Consultancy; AstraZeneca and Korea Health Industry Development Institute: Research Funding; AstraZeneca: Consultancy. Lakhani:incyte: Research Funding; merck: Research Funding; mersana: Research Funding; northern biologics: Research Funding; odonate: Research Funding; pfizer: Research Funding; ikena: Research Funding; symphogen: Research Funding; taiRx: Research Funding; tesaro: Research Funding; livzon: Research Funding; loxo: Research Funding; macrogenics: Research Funding; inhibRx: Research Funding; cytomx: Research Funding; formation biologics: Research Funding; forty seven inc: Research Funding; alexion Pharmaceuticals: Research Funding; Alpine Biosciences: Research Funding; ALX Oncology Inc.: Research Funding; Apexian: Research Funding; asana biosciences: Research Funding; ascentage pharma: Research Funding; beigene: Research Funding; celgene: Research Funding; cerulean pharma: Research Funding; constellation pharma: Research Funding; coordination therapeutics: Research Funding; regeneron: Research Funding; sapience therapeutics: Research Funding; shattuck labs: Research Funding; innovent bio: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; jounce therapeutics: Research Funding. Gainor:theravance: Consultancy; adaptimmune: Research Funding; ariad: Research Funding; astrazeneka: Research Funding; blueprint medicines: Research Funding; lily: Consultancy; gilead sciences: Consultancy; merck: Consultancy, Research Funding; moderna therapeutics: Consultancy, Research Funding; tesaro: Research Funding; blueprint medicines: Consultancy; novartis: Research Funding; oncorus: Consultancy; regeneron: Consultancy; bristol-myers Squibb: Consultancy, Research Funding; amgen: Consultancy; array biopharma: Consultancy, Research Funding; agios: Consultancy; ironwood pharmaceuticals: Consultancy; takeda: Consultancy; genentech: Consultancy, Research Funding; jounce therapeutics: Consultancy, Research Funding. Kamdar:Roche: Research Funding. Fanning:ALX Oncology Inc.: Current Employment, Current equity holder in publicly-traded company. Squifflet:ALX Oncology Inc.: Consultancy; IDDI: Current Employment. Jin:ALX Oncology Inc.: Current Employment. Forgie:ALX Oncology Inc.: Current Employment, Current equity holder in publicly-traded company; Pfizer Inc.: Ended employment in the past 24 months. Wan:Tallac Therapeutics: Current Employment, Current equity holder in private company; ALX Oncology Inc.: Consultancy, Current equity holder in publicly-traded company. Pons:ALX Oncology Inc.: Current Employment, Current equity holder in publicly-traded company. Randolph:ALX Oncology Inc.: Current Employment, Current equity holder in publicly-traded company. Kim:F. Hoffmann-La Roche: Research Funding; Pfizer: Research Funding; JJ: Research Funding; Celltrion: Research Funding; Kyowa Kirn: Research Funding; Donga: Research Funding; Mundipharma: Research Funding.

scholarly journals Primary ovarian non-Hodgkin lymphoma: Diagnosis of two cases on fine needle aspiration cytology

CytoJournal ◽  
2016 ◽  
Vol 13 ◽  
pp. 2 ◽  
Author(s):  
Rajni Yadav ◽  
Partheeban Balasundaram ◽  
Asit R. Mridha ◽  
Venkateswaran K. Iyer ◽  
Sandeep R. Mathur
Keyword(s):  
Hodgkin Lymphoma ◽  
Fine Needle Aspiration ◽  
Fine Needle Aspiration Cytology ◽  
Systemic Disease ◽  
B Cell Lymphoma ◽  
Needle Aspiration ◽  
Aspiration Cytology ◽  
Fine Needle ◽  
Non Hodgkin Lymphoma ◽  
Needle Aspiration Cytology

Lymphoma of the female genital tract is a rare condition. Involvement of the ovary by non- Hodgkin lymphoma (NHL) is usually secondary to systemic disease and primary ovarian lymphomas are unusual. In most cases, the diagnosis is not suspected initially and is confirmed only after detailed histopathological evaluation. We describe two cases of primary ovarian NHL which were diagnosed on fine needle aspiration cytology (FNAC). One of the patients was a 40 years old female who presented with abdominal distension and lump. She was found to have bilateral adnexal masses on ultrasound and computed tomography (CT) scan. A USG guided fine needle aspiration of the ovarian masses was performed, following which a diagnosis of primary ovarian diffuse large B-cell lymphoma was established. The second patient was a 14 years old female who presented with pelvic lump, which was lobulated and mildly enhancing on contrast enhanced CT. A diagnosis of high grade NHL of ovaries was made on cytology. Subsequently, the lymphoma was characterized as Burkitt's on histopathological examination. Both the patients were started on R-CHOP chemotherapy regimen. FNAC serves as an extremely useful minimally invasive procedure for the diagnosis of ovarian lymphomas and early institution of appropriate chemotherapeutic regimens.

Non-Hodgkin Lymphoma: Low Grade

2015 ◽  
pp. 614-630
Author(s):  
William Townsend ◽  
Robert Marcus
Keyword(s):  
Hodgkin Lymphoma ◽  
Low Grade ◽  
Non Hodgkin Lymphoma

Disease Spectrum of Cervical Lymphadenopathy in adults

2021 ◽  
Vol 15 (11) ◽  
pp. 2853-2855
Author(s):  
Rabia Amin Butt ◽  
Zonaira Rathore ◽  
Afia Sarwar ◽  
Faiza Azam ◽  
Faria Waqar Khan ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Tertiary Care ◽  
Cervical Lymphadenopathy ◽  
Diagnostic Tools ◽  
Tuberculous Lymphadenitis ◽  
Care Hospital ◽  
Inclusion Criteria ◽  
Non Hodgkin Lymphoma ◽  
Malignant Lesions ◽  
Age Range

Aim: To determine the frequency of different diseases resulting in cervical lymphadenopathy in specimens of patients presenting in tertiary care hospital. Methodology: It was a cross sectional study conducted at the histopathology section of the pathology department of Services Institute of Medical Sciences/Services Hospital Lahore. The study was approved by the ethical committee of the institution. The study was completed in six months.100 cases fulfilling the inclusion criteria were registered. Inclusion criteria included patients above 16 years of age, patients from both sexes, unilateral or bilateral irrespective of duration. Lymph nodes less than 1cm were not included in the study. Informed consent was taken. Both FNAC and Biopsy were used as diagnostic tools. All the data was analysed with SPSS version 11. Results: During a period of six months, a total of 100 cases of cervical lymphadenopathy were studied. These included 75 benign and 25 malignant cases. Out of benign cases 53% were diagnosed as tuberculous lymphadenitis. About 81.3% were in the age range of 16-25 years and 18.7% were in the age range of 26-35 years. 22% cases were diagnosed as reactive lymphadenitis. About 54.54% of these patients were in the age range of 16-25 years and 45.46% were in the age range of 26-35 years. The highest frequency among malignant lesions consisted of Non-Hodgkin lymphoma 16% followed by Hodgkin lymphoma 5% and metastatic disease 4%.The age range of malignant lesions was in the range of 36-78 years. Conclusion: Our study concludes that cervical lymphadenopathy is the common clinical presentation in our setup and tuberculosis is the commonest cause. Keywords: Hodgkin lymphoma, Non-Hodgkin lymphoma, Fine needle aspiration cytology

scholarly journals Prognostic factors in non-Hodgkin lymphomas

2000 ◽  
Vol 118 (1) ◽  
pp. 7-12 ◽  
Author(s):  
Karin Zattar Cecyn ◽  
José Salvador Rodrigues de Oliveira ◽  
Antônio Correia Alves ◽  
Maria Regina Regis Silva ◽  
José Kerbauy
Keyword(s):  
Prognostic Factors ◽  
Hodgkin Lymphoma ◽  
Low Grade ◽  
High Grade ◽  
Cns Involvement ◽  
Intermediate Grade ◽  
Non Hodgkin Lymphoma ◽  
Tumor Dissemination ◽  
Mediastinal Disease ◽  
Extranodal Disease

CONTEXT: In Hodgkin's disease, each clinical or pathologic stage can be related to the extent of the area involved and predicts the next anatomical region at risk for tumor dissemination. OBJECTIVE: To determine the best prognostic factors that could predict survival in non-Hodgkin lymphoma cases. DESIGN: A retrospective study. LOCATION: Department of Hematology and Transfusion Medicine, Universidade Federal de São Paulo - Escola Paulista de Medicina. PARTICIPANTS: 142 patients with non-Hodgkin lymphoma diagnosed between February 1988 and March 1993. MAIN MEASUREMENTS: Histological subset, Sex, Age, Race, B symptoms, Performance status, Stage, Extranodal disease, Bulk disease, Mediastinal disease, CNS involvement, BM infiltration, Level of DHL, Immunophenotype. RESULTS: In the first study (113 patients), the following variables had a worse influence on survival: yellow race (P<0.1); ECOG II, III e IV (P<0.1) and extranodal disease (P<0.1) for high grade lymphomas; constitutional symptoms (P<0.1), ECOG II, III e IV (P<0.1) and involvement of CNS (P<0.1) for intermediate grade and the subtype lymphoplasmocytoid (P=0.0186) for low grade lymphomas. In the second survey (93 patients), when treatment was included, the variables related to NHL survival were: CNS involvement (P<0.1) for high grade lymphomas, constitutional symptoms (P<0.1), ECOG II, III, IV (P=0.0185) and also CNS involvement (P<0.1) for the intermediate group. There were no variables related to the survival for low-grade lymphomas. CONCLUSIONS: The intermediate grade lymphomas were more compatible with data found in the literature, probably because of the larger number of patients. In this specific case, the treatment did not have an influence on the survival.

Sign in / Sign up

Export Citation Format

Share Document